Conversely, GA attenuated the impact of IL-6, and co-treatment of GA with STAT3/Notch inhibitors further reduced the influence of IL-6, implying that GA inhibited the malignant activities of ESCC and enhanced the sensitivity of DDP chemotherapy by blocking the IL-6/STAT3/Notch pathway. Here, STAT3 is linked to esophageal squamous cell carcinoma.